11 Prostate Cancer
11 前列腺癌
基本信息
- 批准号:10655550
- 负责人:
- 金额:$ 1.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-08-28 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAndrogen AntagonistsAndrogen ReceptorAndrogensAntigen-Presenting CellsBiologicalBiological MarkersBiological ModelsBiologyBloodBlood TestsCHEK1 geneCTLA4 blockadeCancer BiologyCancer Center Support GrantCancer PatientCell CommunicationCellsClinicClinicalClinical ResearchClinical Trials DesignCollaborationsDevelopmentDiseaseDrug resistanceEndothelial CellsEpitheliumEvolutionExperimental ModelsFRAP1 geneFailureFibroblast Growth FactorFundingGene Expression ProfileGenerationsGenetically Engineered MouseGenetsGenomicsGoalsGrantGrowth FactorHeterogeneityImmuneImmune TargetingImmune responseImmunologyImmunotherapyInternationalJournalsKDR geneKnowledgeLaboratoriesLaboratory ScientistsLinkMacrophageMalignant NeoplasmsMalignant neoplasm of prostateMarrowMediatingMedical OncologistMetastatic Neoplasm to the BoneMethodsModelingMolecularMutationMyeloid-derived suppressor cellsNatureNew AgentsPI3K/AKTPaperPatientsPeer ReviewPhenotypePhysiciansPlatinumPoly(ADP-ribose) Polymerase InhibitorPrediction of Response to TherapyProstate Cancer therapyPublicationsPublishingRadiumReceptor SignalingRecurrent tumorRefractoryReportingResearchResistanceResource SharingRoleScientistSignal PathwaySignal TransductionSystemT-LymphocyteTechnologyTestingTherapeuticTimeTissue SampleTissuesTranslatingTumor BiologyTumor TissueUrineVariantbeta cateninbiomarker identificationbonecancer cellcarcinogenesisclinical applicationclinical developmentclinical efficacyclinically relevanteffective therapyepigenomicsexosomeimmune checkpoint blockadeimprovedinhibitorinsightliquid biopsymembermenmetabolomicsneoplastic cellnovelnovel therapeutic interventionnovel therapeuticspatient derived xenograft modelpatient responsepredict responsivenesspredicting responsepredictive markerprognosticationprogramsprogression markerprostate biopsyprostate cancer cellprostate cancer progressionresistance mechanismresponsestandard of caretargeted agenttargeted treatmenttherapy developmenttissue resourcetooltreatment responsetumortumor microenvironment
项目摘要
PROJECT SUMMARY/ABSTRACT
The Prostate Cancer Program (PCaP) consists of 50 members (30 primary, 18 associate, 2 adjunct) from 16
departments. The program is led by Dr. Christopher J. Logothetis, an internationally recognized medical
oncologist, and co-led by Drs. Timothy C. Thompson, a laboratory scientist, and Filippo Giancotti, an
accomplished physician-scientist. The major scientific goal of the PCaP is to build on our understanding of
prostate cancer to develop more effective treatment and improve standard of care. The program is organized
around 3 themes: 1) Biomarkers for Progression and Prediction; 2) Targeting the Immune and Non-immune
Components of the Microenvironment, including the immune component; and 3) Targeting Cancer Cell Signaling.
Each theme is addressed by a specific aim. Aim 1: To develop new tests from blood, urine, and tumor tissues
that predict tumor recurrence, progression, and sensitivity or resistance to existing and novel therapies. Aim 2:
To understand tumor cell-host interactions and translate this knowledge into the development of novel
therapeutic approaches targeting the microenvironment. Aim 3: To target prostate cancer cell signaling with
novel single agents and with combinations of agents used sequentially or concurrently. The annual direct peer-
reviewed funding totals $3,693,347, including a Prostate Cancer SPORE, and $2,204,086 (60%) is from NCI
grants. Since the last submission, the program has authored 350 published papers, of which 183 (52%) are intra-
programmatic, 112 (32%) are inter-programmatic, and 245 (70%) are external collaborations. Forty-nine percent
of publications appeared in journals with IF >5 and 23% appeared in journals with IF >10, including Cancer Cell,
Lancet Oncol, Proc Natl Acad Sci USA, Nature, N Engl J Med, Cell, Nat Genet, J Natl Cancer Inst, Sci Transl
Med, and J Clin Oncol. Program members use all 14 shared resources. Over the past 6 years, the PCaP has 1)
discovered biomarkers that predict responsiveness or initial/acquired resistance to the second-generation
androgen receptor signaling inhibitors; 2) identified biomarkers associated with the “aggressive variant” prostate
cancer phenotype that predict response to platinum-based combinations in clinical and co-clinical models; 3)
discovered immunotherapy targets in prostate cancer (e.g., VISTA) that are expressed on T cells and antigen-
presenting cells, including macrophages; 4) linked myeloid-derived suppressor cells with immune checkpoint
blockade resistance in prostate cancer; 5) identified FGF as a target in prostate cancer, providing a mechanism
of action for the VEGFR and c-met inhibitor cabozantinib; 6) elucidated the impact of cross-talk between
PI3K/AKT/mTOR signaling in regulating efficacy of targeted therapy for prostate cancer; 7) identified prostate
cancer vulnerability to PARP inhibitors regulated by androgen inhibitor-mediated BRCAness; and 8) identified
cancer-induced transition of endothelial cells to cells with osteoblastic function and associated them with bone
metastases.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher J. Logothetis其他文献
Model Systems of Prostate Cancer: Uses and Limitations
- DOI:
10.1023/a:1006165017279 - 发表时间:
1998-12-01 - 期刊:
- 影响因子:8.700
- 作者:
Nora M. Navone;Christopher J. Logothetis;Andrew C. von Eschenbach;Patricia Troncoso - 通讯作者:
Patricia Troncoso
Osteoblasts in prostate cancer metastasis to bone
前列腺癌骨转移中的成骨细胞
- DOI:
10.1038/nrc1528 - 发表时间:
2005-01-01 - 期刊:
- 影响因子:66.800
- 作者:
Christopher J. Logothetis;Sue-Hwa Lin - 通讯作者:
Sue-Hwa Lin
1459: Preliminary Results of a Phase III Trial of Hormonal Therapy vs. Chemohormonal Therapy as Initial Treatment for Non-Localized Prostate Cancer
- DOI:
10.1016/s0022-5347(18)38684-1 - 发表时间:
2004-04-01 - 期刊:
- 影响因子:
- 作者:
Randall E. Millikan;Melissa Brown;Brenda Moomey;Christopher J. Logothetis - 通讯作者:
Christopher J. Logothetis
784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS
- DOI:
10.1016/j.juro.2013.02.348 - 发表时间:
2013-04-01 - 期刊:
- 影响因子:
- 作者:
Neal Shore;Ethan Basch;Charles J. Ryan;Peter Mulders;Thian Kheoh;Karim Fizazi;Christopher J. Logothetis;Dana Rathkopf;Matthew R. Smith;Paul N. Mainwaring;Yanni Hao;Thomas Griffin;Susan Li;Michael L. Meyers;Arturo Molina;Charles Cleeland - 通讯作者:
Charles Cleeland
Carboplatin and ifosfamide and selective consolidation in advanced seminoma.
卡铂和异环磷酰胺以及晚期精原细胞瘤的选择性巩固。
- DOI:
- 发表时间:
1995 - 期刊:
- 影响因子:8.4
- 作者:
Robert J. Amato;J. Ellerhorst;Marie Banks;Christopher J. Logothetis - 通讯作者:
Christopher J. Logothetis
Christopher J. Logothetis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher J. Logothetis', 18)}}的其他基金
Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE
MD 安德森癌症中心前列腺癌 SPORE 的行政补充
- 批准号:
10704453 - 财政年份:2009
- 资助金额:
$ 1.87万 - 项目类别:
MD Anderson Cancer Center Prostate Cancer SPORE
MD 安德森癌症中心前列腺癌孢子
- 批准号:
9767055 - 财政年份:2009
- 资助金额:
$ 1.87万 - 项目类别:
MD Anderson Cancer Center Prostate Cancer SPORE
MD 安德森癌症中心前列腺癌孢子
- 批准号:
10005121 - 财政年份:2009
- 资助金额:
$ 1.87万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 1.87万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 1.87万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 1.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 1.87万 - 项目类别:
Studentship